Investing in ASSERTIO THERAPEUTICS, INC (ASRT)  ➔  Intrinsic value

Prev. close$1.02 
Previous Close$1.02  
Valuation MethodValuePotential 
Chepakovich Model$0.00-100%recalculate
Graham Formula$32.49+3,086%recalculate

Latest news

Company description

Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version of tapentadol for the management of moderate to severe acute pain. The company has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.